Ambrx: Ambrx Biopharma stock doubles on JNJ deal
Shares of Ambrx Biopharma Inc (NASDAQ: AMAM) roughly doubled this morning after Johnson & Johnson (NYSE: JNJ) revealed plans of acquiring the clinical-stage biopharmaceutical company. Details of the JNJ-Ambrx deal Johnson & Johnson is willing to pay about $2.0 billion to buy the Nasdaq-listed firm. The definitive agreement values each of its share at $28. [...]
Read full article »
Ambrx is a California-based biopharmaceutical company that researches and develops antibody drug conjugates for the treatment of cancer.
Read more